These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28278723)

  • 21. Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia.
    Chen X; Yang W; Zhu X
    Pediatr Int; 2011 Aug; 53(4):598-600. PubMed ID: 21851498
    [No Abstract]   [Full Text] [Related]  

  • 22. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
    Heibl S; Buxhofer-Ausch V; Schmidt S; Webersinke G; Lion T; Piringer G; Kuehr T; Wolf D; Melchardt T; Greil R; Thaler J
    Hematol Oncol; 2020 Dec; 38(5):792-798. PubMed ID: 32757230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
    Liu NS; O'Brien S
    Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
    Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
    Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
    Berger U; Hehlmann R
    Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
    [No Abstract]   [Full Text] [Related]  

  • 31. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
    Stagno F; Stella S; Berretta S; Massimino M; Antolino A; Giustolisi R; Messina A; Di Raimondo F; Vigneri P
    Leuk Res; 2008 Apr; 32(4):673-4. PubMed ID: 17889935
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.
    Zhu J; Ding B; Li Y
    Leuk Lymphoma; 2013 Jul; 54(7):1426-9. PubMed ID: 23270584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
    Buxhofer-Ausch V; Hinterberger-Fischer M; Hinterberger W
    Eur J Haematol; 2006 May; 76(5):447-8. PubMed ID: 16494624
    [No Abstract]   [Full Text] [Related]  

  • 34. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
    Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
    Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience.
    Edesa WA; Abdel-malek RR
    J Egypt Natl Canc Inst; 2015 Jun; 27(2):69-75. PubMed ID: 25882857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis].
    Kitajima K; Adachi T; Takahashi I; Nakada H; Osada K; Fukuda S; Ohmoto E; Aoyama S; Yorimitsu S; Sanada H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3573-9. PubMed ID: 2817908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
    Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
    Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.